Fusogenic peptide delivery of bioactive siRNAs targeting CSNK2A1 for treatment of ovarian cancer

Siegel, 2021, Cancer statistics, 2021, CA. Cancer J. Clin., 71, 7, 10.3322/caac.21654 Srivastava, 2017, Racial health disparities in ovarian cancer: not just black and white, J. Ovarian Res., 10, 58, 10.1186/s13048-017-0355-y National Cancer Institute, and DCCPS Surveillance, Epidemiology, and End Results (SEER) Program. Research Data (1975-2019). National Cancer Institute. Grunewald, 2017, Targeted therapies for ovarian cancer, Best Pract. Res. Clin. Obstet. Gynaecol., 41, 139, 10.1016/j.bpobgyn.2016.12.001 Champer, 2018, Adherence to treatment recommendations and outcomes for women with ovarian cancer at first recurrence, Gynecol. Oncol., 148, 19, 10.1016/j.ygyno.2017.11.008 Alexander-Bryant, 2017, Dual peptide-mediated targeted delivery of bioactive siRNAs to oral cancer cells in vivo, Oral Oncol., 72, 123, 10.1016/j.oraloncology.2017.07.004 Qin, 2013, Development of cholesteryl peptide micelles for siRNA delivery, J. Control. Release, 172, 159, 10.1016/j.jconrel.2013.07.033 Karagiannis, 2012, Rationally designed tumor-penetrating nanocomplexes, ACS Nano, 6, 8484, 10.1021/nn304707b Kim, 2010, RNA interference in vitro and in vivo using an arginine peptide/siRNA complex system, J. Control. Release, 143, 335, 10.1016/j.jconrel.2010.01.009 Kim, 2007, Strategies for silencing human disease using RNA interference, Nat. Rev. Genet., 8, 173, 10.1038/nrg2006 Ozcan, 2016, Preclinical and clinical development of siRNA therapeutics, Adv. Drug Deliv. Rev., 87, 108, 10.1016/j.addr.2015.01.007 Alexander-Bryant, 2013, Bioengineering strategies for designing targeted cancer therapies, Adv. Cancer Res., 118, 1, 10.1016/B978-0-12-407173-5.00002-9 Goldberg, 2013, SiRNA delivery for the treatment of ovarian cancer, Methods, 63, 95, 10.1016/j.ymeth.2013.01.007 Lehto, 2016, Peptides for nucleic acid delivery, Adv. Drug Deliv. Rev., 106, 172, 10.1016/j.addr.2016.06.008 Tai, 2017, Functional peptides for siRNA delivery, Adv. Drug Deliv. Rev., 110–111, 157, 10.1016/j.addr.2016.08.004 Erazo-oliveras, 2012, Improving the endosomal escape of cell-penetrating peptides and their cargos : strategies and challenges, Pharmaceuticals, 5, 1177, 10.3390/ph5111177 Oliveira, 2007, Fusogenic peptides enhance endosomal escape improving siRNA-induced silencing of oncogenes, Int. J. Pharm., 331, 211, 10.1016/j.ijpharm.2006.11.050 Nishimura, 2014, A display of pH-sensitive fusogenic GALA peptide facilitates endosomal escape from a Bio-nanocapsule via an endocytic uptake pathway, J. Nanobiotechnol., 12, 11, 10.1186/1477-3155-12-11 Cummings, 2019, Peptide carriers to the rescue: overcoming the barriers to siRNA delivery for cancer treatment, Transl. Res., 214, 92, 10.1016/j.trsl.2019.07.010 Samec, 2022, Peptide-based delivery of therapeutics in cancer treatment, Mater. Today. Bio, 14, 100248, 10.1016/j.mtbio.2022.100248 Cantini, 2013, Fusogenic-Oligoarginine peptide-mediated delivery of siRNAs targeting the CIP2A oncogene into oral cancer cells, PLoS One, 8, e73348, 10.1371/journal.pone.0073348 Burks, 2015, Co-encapsulating the fusogenic peptide INF7 and molecular imaging probes in liposomes increases intracellular signal and probe retention, PLoS One, 10, e0120982, 10.1371/journal.pone.0120982 Subbarao, 1987, pH-dependent bilayer destabilization by an amphipathic peptide, Biochemistry, 26, 2964, 10.1021/bi00385a002 Alexander-Bryant, 2015, Fusogenic-oligoarginine peptide-mediated silencing of the CIP2A oncogene suppresses oral cancer tumor growth in vivo, J. Control. Release, 218, 72, 10.1016/j.jconrel.2015.09.026 Sackett, 2005, The HIV fusion peptide adopts intermolecular parallel β-sheet structure in membranes when stabilized by the adjacent N-terminal heptad repeat: a 13C FTIR study, J. Mol. Biol., 350, 790, 10.1016/j.jmb.2005.05.030 Domcke, 2013, Evaluating cell lines as tumour models by comparison of genomic profiles, Nat. Commun., 4, 2126, 10.1038/ncomms3126 Rabalski, 2016, Molecular pathways: emergence of protein kinase CK2 (CSNK2) as a potential target to inhibit survival and DNA damage response and repair pathways in cancer cells, Clin. Cancer Res., 22, 2840, 10.1158/1078-0432.CCR-15-1314 Ma, 2017, Increased expression of protein kinase CK2α correlates with poor patient prognosis in epithelial ovarian cancer, PLoS One, 12, e0174037, 10.1371/journal.pone.0174037 Litchfield, 2003, Protein kinase CK2: structure, regulation and role in cellular decisions of life and death, Biochem. J., 369, 1, 10.1042/bj20021469 Chua, 2017, CK2 in cancer: cellular and biochemical mechanisms and potential therapeutic target, Pharmaceuticals, 10, E18, 10.3390/ph10010018 Pathak, 2015, A synthetic lethality screen using a focused siRNA library to identify sensitizers to dasatinib therapy for the treatment of epithelial ovarian cancer, PLoS One, 10, e0144126, 10.1371/journal.pone.0144126 Siddiqui-Jain, 2012, CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy, Mol. Cancer Ther., 11, 994, 10.1158/1535-7163.MCT-11-0613 Li, 2004, GALA: a designed synthetic pH-responsive amphipathic peptide with applications in drug and gene delivery, Adv. Drug Deliv. Rev., 56, 967, 10.1016/j.addr.2003.10.041 Sánchez-García, 2017, The fusogenic peptide HA2 impairs selectivity of CXCR4-targeted protein nanoparticles, Chem. Commun., 53, 4565, 10.1039/C6CC09900A Thomas, 2019, Overcoming physiological barriers to nanoparticle delivery—are we there yet?, Front. Bioeng. Biotechnol., 7, 415, 10.3389/fbioe.2019.00415 Hou, 2015, A role for peptides in overcoming endosomal entrapment in siRNA delivery – a focus on melittin, Biotechnol. Adv., 33, 931, 10.1016/j.biotechadv.2015.05.005 He, 2015, Self-assembled nanoscale coordination polymers carrying siRNAs and cisplatin for effective treatment of resistant ovarian cancer, Biomaterials, 36, 124, 10.1016/j.biomaterials.2014.09.017 Roberts, 2017, Nanoparticle delivery of siRNA against TWIST to reduce drug resistance and tumor growth in ovarian cancer models, Nanomedicine., 13, 965, 10.1016/j.nano.2016.11.010 Leng, 2009, Advances in systemic siRNA delivery, Drugs Future, 34, 721, 10.1358/dof.2009.34.9.1413267 Kanekura, 2018, Characterization of membrane penetration and cytotoxicity of C9orf72-encoding arginine-rich dipeptides, Sci. Rep., 8, 12740, 10.1038/s41598-018-31096-z Pei, 2019, Overcoming endosomal entrapment in drug delivery, Bioconjug. Chem., 30, 273, 10.1021/acs.bioconjchem.8b00778 Meng, 2017, Histidine-enriched multifunctional peptide vectors with enhanced cellular uptake and endosomal escape for gene delivery, J. Mater. Chem. B, 5, 74, 10.1039/C6TB02862D Midoux, 1999, Efficient gene transfer by histidylated polylysine/pDNA complexes, Bioconjug. Chem., 10, 406, 10.1021/bc9801070 Kumar, 2003, Single histidine residue in head-group region is sufficient to impart remarkable gene transfection properties to cationic lipids: evidence for histidine-mediated membrane fusion at acidic pH, Gene Ther., 10, 1206, 10.1038/sj.gt.3301979 Evans, 2017, Folate-targeted amphiphilic cyclodextrin nanoparticles incorporating a fusogenic peptide deliver therapeutic siRNA and inhibit the invasive capacity of 3D prostate cancer tumours, Int. J. Pharm., 532, 511, 10.1016/j.ijpharm.2017.09.013 Christiaens, 2002, Tryptophan fluorescence study of the interaction of penetratin peptides with model membranes, Eur. J. Biochem., 269, 2918, 10.1046/j.1432-1033.2002.02963.x Lönn, 2016, Enhancing endosomal escape for intracellular delivery of macromolecular biologic therapeutics, Sci. Rep., 10.1038/srep32301 Bae, 2016, CK2α/CSNK2A1 phosphorylates SIRT6 and is involved in the progression of breast carcinoma and predicts shorter survival of diagnosed patients, Am. J. Pathol., 186, 3297, 10.1016/j.ajpath.2016.08.007 Jiang, 2019, Csnk2a1 promotes gastric cancer invasion through the pi3k-akt-mtor signaling pathway, Cancer Manag. Res., 11, 10135, 10.2147/CMAR.S222620 Dubois, 2016, Constitutive activation of casein kinase 2 in glioblastomas: absence of class restriction and broad therapeutic potential, Int. J. Oncol., 48, 2445, 10.3892/ijo.2016.3490 Sharma, 2019, Ovarian cancer G protein-coupled receptor 1 inhib- its A549 cells Migration through Casein kinase 2 α intronless gene and Neutral endopeptidase, BMC Cancer, 22, 143, 10.1186/s12885-022-09257-1 Bae, 2015, CK2α phosphorylates DBC1 and is involved in the progression of gastric carcinoma and predicts poor survival of gastric carcinoma patients, Int. J. Cancer, 136, 797, 10.1002/ijc.29043 Ortega, 2014, Mining CK2 in cancer, PLoS One, 9, e115609, 10.1371/journal.pone.0115609 Zhou, 2016, Protein kinase CK2α maintains extracellular signal-regulated kinase (ERK) activity in a CK2α kinase-independent manner to promote resistance to inhibitors of RAF and MEK but not ERK in BRAF mutant melanoma, J. Biol. Chem., 291, 17804, 10.1074/jbc.M115.712885 Marcotte, 2012, Essential gene profiles in breast, pancreatic, and ovarian cancer cells, Cancer Discov., 2, 172, 10.1158/2159-8290.CD-11-0224 Beaufort, 2014, Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes, PLoS One, 9, e103988, 10.1371/journal.pone.0103988 Tudrej, 2019, Characteristics of in vivo model systems for ovarian cancer studies, Diagnostics, 9, 120, 10.3390/diagnostics9030120 Hernandez, 2016, Characterization of ovarian cancer cell lines as in vivo models for preclinical studies, Gynecol. Oncol., 142, 332, 10.1016/j.ygyno.2016.05.028 Ryu, 2021, Novel fusion peptide-mediated siRNA delivery using self-assembled nanocomplex, J. Nanobiotechnol., 19, 44, 10.1186/s12951-021-00791-x Liu, 2014, Tumor-targeted in vivo gene silencing via systemic delivery of cRGD-conjugated siRNA, Nucleic Acids Res., 42, 11805, 10.1093/nar/gku831 Huang, 2015, Systemic administration of siRNA via cRGD-containing peptide, Sci. Rep., 5, 12458, 10.1038/srep12458 Ikemoto, 2017, Hyaluronan-binding peptide for targeting peritoneal carcinomatosis, Tumour Biol., 39, 10.1177/1010428317701628 Simón-Gracia, 2018, Peritoneal carcinomatosis targeting with tumor homing peptides, Molecules, 23, E1190, 10.3390/molecules23051190 Hunt, 2017, Targeting of p32 in peritoneal carcinomatosis with intraperitoneal linTT1 peptide-guided pro-apoptotic nanoparticles, J. Control. Release, 260, 142, 10.1016/j.jconrel.2017.06.005 Persengiev, 2004, Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs), RNA, 10, 12, 10.1261/rna5160904